Sixfold Bioscience
Sixfold Bioscience develops the Mergo platform to solve delivery challenges for RNA-based therapies. The company utilizes a combination of evolutionary biology principles and artificial intelligence to engineer targeted delivery systems. Their technology aims to enable the development of future RNA therapeutics by ensuring genetic material reaches specific cellular targets.
Visit websiteLondon, UK
Biotechnology
Healthtech
Artificial Intelligence
Funding summary
- Total raised
- €9.2M
- Funding rounds
- 1
Investors in Sixfold Bioscience
Investors on record for Sixfold Bioscience. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Sixfold Bioscience?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors